FGF21 and metabolic dysfunction-associated steatohepatitis: The protective anti-obesity (including the obesity complications), anti-diabetes, and anti-inflammation effects of pharmacological FGF21 have been extensively studied in models of fatty liver disease including hepatosteatosis, non-alcoholic steatohepatitis (NASH), and in malignancies such as hepatocellular carcinoma [162,163,164,165,166,167].